Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist developed by Eli Lilly, FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) including severe obstructive sleep apnea in adults with obesity. It is a 39-amino-acid peptide with a C20 fatty di-acid moiety that promotes albumin binding, enabling once-weekly dosing. Clinical trials consistently demonstrate it delivers the most substantial weight reduction among incretin-based therapies, with up to 22.5% mean body weight loss at 72 weeks.
Typical dose
2.5-15mg weekly
Weekly, increase every 4 weeks
Route
Subcutaneous weekly
Inject once weekly on the same day. Can be administered any time of day, with or without meals.
Cycle
12-24+ weeks
Typical duration
Storage
2-8°C
Follow vendor guidance
Marketplace
10 offers for Tirzepatide
| Vendor | Price | Rating | Shipping | COA | Action |
|---|---|---|---|---|---|
HLX LABS
| $32.99 $49.99 $3.30/mg −34% | No reviews | 2–5 days United States | 1 file | |
bioinfinity
| $50.00 $10.00/mg | No reviews | 3–5 days United States, Puerto Rico | 1 file | |
Trulab Peptides
| $55.00 $11.00/mg | No reviews | 2–5 days Worldwide | 1 file | |
Peptix USA
| $58.00 $2.90/mg | No reviews | 3–5 days United States | None | |
Giga Compounds
| $60.00 $3.00/mg | No reviews | 2 days United States | 1 file | |
prpeps
| $60.00 $6.00/mg | No reviews | 2 days United States | None | |
Crownwell Research
| $90.00 $9.00/mg | No reviews | 1-5 days United States | 3 files | |
American Peptides
| $100.00 $10.00/mg | No reviews | 1-2 days United States | 3 files |
What the research reports
Outcomes described across the published literature and ongoing study, not promised results. Read each as research context, not a personal guarantee.
Significant weight loss
Dual receptor activation
Glycemic control
Appetite suppression
Dosage and protocol
Tirzepatide is a dual GIP/GLP-1 receptor agonist for weight management and diabetes. Like semaglutide, it requires gradual dose titration starting at 2.5mg weekly. Half-life: ~5 days.
01 Route
Subcutaneous weekly
02 Example range
2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg
03 Frequency
Weekly, increase every 4 weeks
04 Timing
Inject once weekly on the same day. Can be administered any time of day, with or without meals.
Educational reference only. Use clinician guidance for dosing decisions.
Evidence
SURPASS-CVOT comparing tirzepatide vs dulaglutide for cardiovascular outcomes in type 2 diabetes (ongoing trial).
Tirzepatide noninferior to dulaglutide for cardiovascular outcomes in type 2 diabetes with atherosclerotic disease.
Tirzepatide 5-15mg produced 15-20.9% weight loss with 85-91% achieving ≥5% weight reduction.
Tirzepatide slowed eGFR decline and reduced albuminuria vs insulin glargine in type 2 diabetes.
Tirzepatide achieved greater HbA1c reduction than insulin glargine with lower hypoglycemia risk.
Interactions
SEMAGLUTIDE Caution · Well-documented
Caution: overlapping GLP-1 agonism with increased GI side effect risk. Generally not combined in clinical practice.
FAQ
Tirzepatide is a dual GLP-1/GIP agonist that has shown exceptional weight loss results in clinical trials. Following FDA compounding restrictions similar to semaglutide, research vendor demand has surged significantly.
Pep Grading
United States